Related Experiment Video
Updated: Aug 15, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Rechallenging nivolumab following immune checkpoint inhibitor-induced pericarditis
Mustafa Rami Ali1, Omar Jamil Darwish1, Laith Alhuneafat2
1Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Abstract:
We report a case of recurrent pericarditis as an immune-related adverse event in a 47-year-old man with de novo metastatic renal cell carcinoma. After first-line treatment with sunitinib failed, he received three cycles of nivolumab and developed pericarditis following each cycle. The third cycle was accompanied by colchicine as a secondary prophylaxis. Pericarditis is an uncommon and potentially life-threatening immune-related adverse event, if not managed promptly.
More Related Videos
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Related Concept Videos
Pericarditis III: Medical Management
Pericarditis IV: Nursing Management
Pericarditis I: Introduction
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Pericarditis II: Clinical Features and Diagnostic Tests